Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Strategies to overcome resistance to EGFR and ALK TKIs

31 Mar 2023

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Translational Research; Targeted Therapy

Non-Small Cell Lung Cancer

Mariana Brandão

M. Brandão

This content is available to ESMO members and event participants.

31 Mar 2023

Presenter: Margarita Majem Tarruella

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Presenter: Xiuning Le

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Presenter: Heather Wakelee

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Webcast